|
|
Improvement method of medical institutions for establishment and examination work of clinical trial project |
CAI Junlong WU Jianyuan CHEN Bo ZHOU Jingjing LIN Jun HUANG Jianying |
Clinical Trial Center, Zhongnan Hospital of Wuhan University, Hubei Province, Wuhan 430071, China |
|
|
Abstract Through analyzing the new policy situations of filling system of clinical trial facility, on-site data verification and other policies, this paper discusses the importance of establishment and examination work of clinical trial project for medical institutions to undertake high quality projects and avoid medical risks. Taking the establishment of project establishment and examination system as the entry point, thia paper briefly expounds the project establishment and examination procedure of medical institutions, namely project negotiation - project application - project preliminary screening and acceptance - project review. In addition, this paper takes multi-dimension and multi-level analsis for the content of project establishment and key problems needing to be paid attention to, discusses the review contents and methods for the important aspects, such as research basis and scientific significance of the project, experiment design, ethical compliance and research team, and emphasizes the key review of whether the project involves activities related to the collection, collection, export and exit of human genetic resources. This paper takes analysis and discussion focusing on the establishment and examination work of clinical trial project, to provide scientific, standard, rigorous and practical management mechanism and specific operation method for reference for medical institutions to establish normalized project establishment and examination procedure, aimed at strengthening the ability of project establishment and examination of medical institutions and ensuring the project quality.
|
|
|
|
|
[1] 国家食品药品监督管理局.药物临床试验质量管理规范(局令第3号)[Z].2003-08-06.
[2] 国家食品药品监督管理局.医疗器械临床试验质量管理规范(国家食品药品监督管理总局、中华人民共和国国家卫生和计划生育委员会委令第25号)[Z].2016-06-01.
[3] 曹彩.药物临床试验科学监管的机遇与挑战[J].中国临床药理学杂志,2009,3(23):270-276.
[4] 国家食品药品监督管理总局.药物临床试验机构资格认定办法(试行)[EB/OL].http://www.sda.gov.cn/WS01/CL0058/9346.html,2004-02-19.
[5] 国家食品药品监管总局国家卫生计生委.医疗器械临床试验机构条件和备案管理办法(2017年第145号)[Z].2017-11-15.
[6] 国家食品药品监管总局办公厅.《药物临床试验机构管理规定(征求意见稿)》[EB/OL].http://www.nmpa.gov.cn/WS04/CL2101/228886.html,2017-10-26.
[7] 国家食品药品监管总局.关于开展药物临床试验数据自查核查工作的公告(2015年第117号)[EB/OL]. http://www.nmpa.gov.cn/WS04/CL2182/299803.html,2015-07-22.
[8] 国务院.关于改革药品医疗器械审评审批制度的意见(国发〔2015〕44号)[EB/OL]. http://www.gov.cn/zhengce/content/2015-08/18/content_10101.htm,2015-08-18.
[9] 中共中央办公厅国务院办公厅.关于深化审评审批制度改革鼓励药品医疗器械创新的意见》(厅字〔2017〕42号)[EB/OL]. http://www.gov.cn/xinwen/2017-10/08/content_5230105.htm,2017-10-08.
[10] 黄一玲,许莉,边文彦,等.以ISO9000质量管理体系理念实施临床试验机构管理[J].中国新药杂志,2014,23(19):2271-2275.
[11] 国家食品药品监督管理总局.药物临床试验的一般考虑指导原则[Z].2017-01-20.
[12] 国家食品药品监督管理总局.关于发布体外诊断试剂临床试验技术指导原则的通告(2014年第16号)[Z].2014-09-11.
[13] 郭晋敏,张莉,舒鹤,等.我院药物临床试验知情同意书设计及签署情况分析[J].中国医药导报,2014,11(12):151-154.
[14] 熊宁宁,王方敏,刘海涛,等.药物临床试验机构的管理原则与要素[J].中国临床药理学与治疗学,2016,21(3):347-353.
[15] 全婷,曾代文,杨友松,等.临床试验伦理委员会初始审查中的主要问题[J].中国医学伦理学,2015,28(1):47-49.
[16] 张莉,郭晋敏,舒鹤,等.我院药物临床试验不良事件监测的方案设计质量调查[J].中国医药导报,2015,12(5):156-160.
[17] 国家食品药品监督管理总局,中华人民共和国国家卫生和计划生育委员会.医疗器械临床试验质量管理规范[Z].2016-03-23.
[18] 刘婧,弭凤玲,赵伟杰,等.临床试验协议管理常见问题[J].解放军医院管理杂志,2018,2(25):135-136,159.
[19] 唐守艳,周铁,陆雯静,等.药物临床试验机构质量控制[J].解放军医院管理杂志,2017,11(24):1098-1100.
[20] 刘峰,邓贵新,李雪芹,等.试验药物管理中存在的问题及对策探讨[J].中国医药导报,2017,14(20):128-131.
[21] 中华人民共和国科学技术部.人类遗传资源管理暂行办法(国办发〔1998〕36号)[Z].1998-06-10.
[22] 中华人民共和国科学技术部.人类遗传资源采集、收集、买卖、出口、出境审批行政许可事项服务指南[Z].2015-07-02.
[23] 中华人民共和国科学技术部.关于开展全国人类遗传资源行政许可管理专项检查有关工作的通知(国科办函社〔2018〕267号)[Z].2018-07-20. |
|
|
|